Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

Thumbnail

AI startup focused on breast cancer screening raises $6M

Niramai Health Analytix, an India-based AI startup, announced that it has closed a $6 million Series A round of funding.

Thumbnail

GE Healthcare IPO likely on hold following $21.4B deal with Danaher

General Electric (GE) may be halting its plan for an initial public offering (IPO) of its healthcare sector in 2019, GE Chairman and CEO Larry Culp told CNBC on Feb. 25. The announcement came after the company made a deal to sell its biopharma business to Danaher for $21.4 billion.

Thumbnail

GE Healthcare IPO ‘unlikely’ in 2019, CEO says

General Electric CEO Larry Culp told CNBC an initial public offering (IPO) for its healthcare unit, GE Healthcare, is unlikely for 2019 following news that the company plans to sell off its biopharma business.

Thumbnail

GE to sell biopharma biz for $21B, postpone healthcare IPO

General Electric Company (GE) is selling its biopharma business to Danaher for $21.4 billion, the company announced Feb. 25. With a definitive agreement signed between the two parties, GE’s previous plan to spin off its healthcare sector with its own initial public offering is likely put on hold, GE Chairman and CEO Larry Culp told CNBC.

GE Healthcare IPO in 2019 ‘unlikely’ after $21.4B deal with Danaher

General Electric (GE) announced on Monday, Feb. 25, that it has entered into a definitive agreement to sell its biopharma business to Danaher Corporation for $21.4 billion. This could significantly impact the company’s plans for an initial public offering (IPO) for GE Healthcare.

Thumbnail

Report reveals drug middlemen snagged $124M in Kentucky

Drug middlemen gobbled up $123.5 million in hidden costs in Kentucky’s Medicaid program, according to a new report from the Kentucky’s Cabinet for Health and Family Services.

Thumbnail

From concept to clearance: Why it’s so expensive to develop new CV drugs

It costs tens of millions of dollars to approve any new therapy for use in a clinical setting, but a recent analysis published in JAMA Internal Medicine found one class of medication comes at a price more than 100-fold higher than the average: cardiovascular drugs.

Thumbnail

Amazon exec: Use AI ethically

Taha Kass-Hout, senior leader of healthcare and AI at Amazon, recently noted the technology and e-commerce giant sees potential in developing healthcare-related AI tools. In an interview with STAT, Kass-Hout didn't divulge many secrets about Amazon's activities with AI, but did talk about certain areas of focus, noting researchers have uncovered “tangible uses of AI."